



PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities

Available to **watch on demand**
from Tuesday 22 September
2020, 09:00AM (CET)

Live chat and Q&A on
Wednesday 23 September
2020, 10:45AM–11.15AM (CET)

SPEAKERS:



TONY MOK
Shatin, Hong Kong



GIORGIO SCAGLIOTTI
Turin, Italy



ANNE-MARIE C. DINGEMANS
Rotterdam, The Netherlands



RAFFAELE CALIFANO
Manchester, United Kingdom

SCHEDULE:

Welcome and Introduction (5 mins)
Tony Mok

PD1 inhibitors for NSCLC: Where are we now? (10 mins)
Tony Mok

One molecule, many mechanisms of action: Why all PD1 inhibitors are not the same (15 mins)
Raffaele Califano

How will the new wave of PD1 inhibitors change the treatment landscape in NSCLC? (15 mins)
Anne-Marie C. Dingemans

What is the impact of PD1 inhibitors for NSCLC in your clinic? A case study discussion (10 mins)
Tony Mok AND Anne-Marie C. Dingemans

PD1 inhibitors for NSCLC: Future challenges, future potential (20 mins)
Giorgio Scagliotti

Exploring the promise of emerging PD1 inhibitors in NSCLC (10 mins)
Giorgio Scagliotti